Last mentioned: Feb 23, 2026
Q4 Earnings Preview
Analysts project significant revenue growth from Amtagvi sales.
Commercial Expansion
Iovance scales ATC network to over 50 centers nationwide.
FDA Approval
Amtagvi receives accelerated approval for metastatic melanoma.
Iovance Biotherapeutics and Fidelity National Financial are preparing to report Q4 2025 results, with investors focusing on the commercial scaling of cell therapies and the resilience of the title insurance market. These reports will provide critical data on biotech commercialization and the health of the U.S. housing sector.
Iovance Biotherapeutics is set to report Q4 2025 results, marking a full year of commercial operations for its breakthrough TIL therapy, Amtagvi. The update will be a critical indicator of the company's ability to scale complex cell therapy logistics and expand its market presence in oncology.
Iovance Biotherapeutics is set to report Q4 2025 results, with investors laser-focused on the commercial trajectory of Amtagvi, the first FDA-approved TIL therapy. The report will provide critical data on treatment center onboarding, patient enrollment, and the company's path toward profitability in the cell therapy space.